Diagnosis, Prognosis, and Mechanisms in Panvascular Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorJinwei Tian
About this trial
This study aims to establish a standardized cohort for panvascular diseases, encompassing biological materials such as DNA samples, along with extensive patient medical records and follow-up information. The design of this database will enable it to serve as a comprehensive resource for future medical research.
Upon data collection, researchers will conduct various statistical analyses to enhance our understanding of the factors and mechanisms contributing to various panvascular diseases, including coronary heart disease, myocardial infarction, stroke, and peripheral vascular disease. These statistical analyses will also aid in identifying more effective treatment strategies for these conditions.
By amassing a large volume of data from a significant number of patients with panvascular diseases, researchers will be able to perform highly precise analyses of the factors influencing the onset, progression, and treatment of these diseases. The results of these precise analyses can then be utilized to optimize clinical practices for the prevention and treatment of panvascular diseases.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Male or female aged 18 to 80 years old;
Diagnosed or suspected panvascular disease, defined as the presence of atherosclerotic lesions in at least two or more vascular regions, such as intracranial arteries, carotid arteries, coronary arteries, aorta, and peripheral arteries;
Voluntary participation in this study and provision of signed informed consent.
Disqualifiers
Severe hemodynamic instability;
Severe cardiac dysfunction (EF < 30%);
Severe arrhythmias;
Severe valvular heart disease;
Trial population
Patients with panvascular diseases
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
No intervention
Other interventionNo intervention
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Number of participants with Cardiovascular mortality, Nonfatal myocardial Infarction, Ischemic stroke, Arteriosclerosis Obliterans
Cardiovascular mortality, Nonfatal myocardial Infarction, Ischemic stroke, Arteriosclerosis Obliterans
Time frame
Up to 5 years from baselineSecondary outcomes
1
All-cause death
Time frame
Up to 5 years from baseline2
Rate of receiving vascular revascularization
Time frame
Up to 5 years from baseline3
Readmission rate for vascular reasons
Time frame
Up to 5 years from baselineSponsors and contacts
Click on the lead sponsor to view all of their trials.
Jinwei Tian
Lead sponsor
Harbin Medical University
Sponsor institution
Source ClinicalTrials.gov